Meningioma

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.Texto completo  Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Texto completo

Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821-34.Texto completo  Resumo

1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(suppl 5):v1-v95.Texto completo  Resumo

2. World Health Organization Classification of Tumours Editorial Board. WHO classification of tumours of the central nervous system. 5th Edition. France: IARC; 2021.

3. Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010;99:393-405. Resumo

4. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.Texto completo  Resumo

5. Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088-1095. Resumo

6. Longstreth WT, Jr, Dennis LK, McGuire VM, et al. Epidemiology of intracranial meningioma. Cancer. 1993;72:639-648.Texto completo  Resumo

7. Benson VS, Pirie K, Green J, et al. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99:185-190.Texto completo  Resumo

8. Harrison MJ, Wolfe DE, Lau TS, et al. Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg. 1991;75:564-574. Resumo

9. Mack EE, Wilson CB. Meningiomas induced by high-dose cranial irradiation. J Neurosurg. 1993;79:28-31. Resumo

10. Shintani T, Hayakawa N, Hoshi M, et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J Radiat Res (Tokyo). 1999;40:49-57.Texto completo  Resumo

11. Bowers DC, Moskowitz CS, Chou JF, et al. Morbidity and mortality associated with meningioma after cranial radiotherapy: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2017 May 10;35(14):1570-76.Texto completo  Resumo

12. Withrow DR, Anderson H, Armstrong GT, et al. Pooled analysis of meningioma risk following treatment for childhood cancer. JAMA Oncol. 2022 Dec 1;8(12):1756-64.Texto completo  Resumo

13. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010 Sep;99(3):307-14.Texto completo  Resumo

14. Lee E, Grutsch J, Persky V, et al. Association of meningioma with reproductive factors. Int J Cancer. 2006 Sep 1;119(5):1152-7.Texto completo  Resumo

15. Sughrue ME, Kane AJ, Shangari G, et al. Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma. J Neurosurg. 2010 Nov;113(5):1115-21. Resumo

16. Shahin MN, Magill ST, Dalle Ore CL, et al. Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. J Neurooncol. 2019 May;143(1):137-44.Texto completo  Resumo

17. Weill A, Nguyen P, Labidi M, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021 Feb 3;372:n37.Texto completo  Resumo

18. Lee KS, Zhang JJY, Kirollos R, et al. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep. 2022 Feb 4;12(1):1942.Texto completo  Resumo

19. Yelehe M, Klein M, El Aridi L, et al. Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database. Fundam Clin Pharmacol. 2022 Dec;36(6):1115-24.Texto completo  Resumo

20. Lee YS, Lee YS. Molecular characteristics of meningiomas. J Pathol Transl Med. 2020 Jan;54(1):45-63.Texto completo  Resumo

21. Ragel BT, Jensen RL, Couldwell WT. Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Neurosurg Focus. 2007;23:E7.Texto completo  Resumo

22. Ragel BT, Jensen RL, Gillespie DL, et al. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer. 2007;109:588-597.Texto completo  Resumo

23. Szychot E, Goodden J, Whitfield G, et al. Children's Cancer and Leukaemia Group (CCLG): review and guidelines for the management of meningioma in children, teenagers and young adults. Br J Neurosurg. 2020 Apr;34(2):142-53. Resumo

24. Ron E, Modan B, Boice JD, Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033-1039. Resumo

25. Preston-Martin S, Henderson BE, Bernstein L. Medical and dental x rays as risk factors for recently diagnosed tumors of the head. Natl Cancer Inst Monogr. 1985;69:175-179. Resumo

26. Hemminki K, Li X, Collins VP. Parental cancer as a risk factor for brain tumors (Sweden). Cancer Causes Control. 2001 Apr;12(3):195-9. Resumo

27. Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54:71-76. Resumo

28. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002;161:665-672.Texto completo  Resumo

29. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002;94:1626-1635.Texto completo  Resumo

30. Jhawar BS, Fuchs CS, Colditz GA, et al. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 2003;99:848-853. Resumo

31. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4:278-99.Texto completo  Resumo

32. Champeaux-Depond C, Weller J, Froelich S, et al. Cyproterone acetate and meningioma: a nationwide-wide population based study. J Neurooncol. 2021 Jan;151(2):331-38. Resumo

33. Hoisnard L, Laanani M, Passeri T, et al. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. Eur J Neurol. 2022 Sep;29(9):2801-9.Texto completo  Resumo

34. Voormolen EHJ, Champagne PO, Roca E, et al. Intracranial meningiomas decrease in volume on magnetic resonance imaging after discontinuing progestin. Neurosurgery. 2021 Jul 15;89(2):308-14. Resumo

35. Bernat AL, Oyama K, Hamdi S, et al. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien). 2015 Oct;157(10):1741-6. Resumo

36. Phillips LE, Koepsell TD, van Belle G, et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology. 2002;58:1849-52. Resumo

37. Kan P, Simonsen SE, Lyon JL, et al. Cellular phone use and brain tumor: a meta-analysis. J Neurooncol. 2008 Jan;86(1):71-8. Resumo

38. Chen F, Wang P, Lan J, et al. Wireless phone use and adult meningioma risk: a systematic review and meta-analysis. Br J Neurosurg. 2021 Aug;35(4):444-50. Resumo

39. Coureau G, Bouvier G, Lebailly P, et al. Mobile phone use and brain tumours in the CERENAT case-control study. Occup Environ Med. 2014;71:514-522. Resumo

40. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Texto completo

41. Kernick DP, Ahmed F, Bahra A, et al. Imaging patients with suspected brain tumour: guidance for primary care. Br J Gen Pract. 2008;58:880-885.Texto completo  Resumo

42. Ownsworth T, Hawkes A, Steginga S, et al. A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature. Disabil Rehabil. 2009;31:1038-1055. Resumo

43. Nakasu S, Fukami T, Nakajima M, et al. Growth pattern changes of meningiomas: long-term analysis. Neurosurgery. 2005;56:946-955. Resumo

44. Oya S, Kim SH, Sade B, et al. The natural history of intracranial meningiomas. J Neurosurg. 2011 May;114(5):1250-6. Resumo

45. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821-34.Texto completo  Resumo

46. Prasad RN, Perlow HK, Bovi J, et al. (68)Ga-DOTATATE PET: the future of meningioma treatment. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):868-71.Texto completo  Resumo

47. Perlow HK, Siedow M, Gokun Y, et al. (68)Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):859-65. Resumo

48. Hadi I, Biczok A, Terpolilli N, et al. Multimodal therapy of cavernous sinus meningioma: Impact of surgery and (68)Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcome. Neurooncol Adv. 2021 Jan-Dec;3(1):vdab114.Texto completo  Resumo

49. Louis D, Scheithauer B, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee W, editors. World Health Organization classification of tumours: pathology and genetics: tumours of the nervous system. Lyon, France: IARC Press, 2000.

50. Englot DJ, Magill ST, Han SJ, et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg. 2016 Jun;124(6):1552-61.Texto completo  Resumo

51. Louis DN, Ohgaki H, Wiestler OD, et al (eds). World Health Organization classification of tumours of the central nervous system. Revised, 4th edition. France: IARC; 2016.

52. Louis DN, Ohgaki H, Westler OD, et al (eds). World Health Organization classification of tumours of the central nervous system. Lyon, France: IARC; 2007.

53. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.Texto completo  Resumo

54. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39. Resumo

55. Komotar RJ, Starke RM, Raper DM, et al. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012;77:713-724. Resumo

56. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1229-1239. Resumo

57. Sheehan J, Pikis S, Islim AI, et al. An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study. Neuro Oncol. 2022 Jan 5;24(1):116-24.Texto completo  Resumo

58. Nakamura M, Roser F, Michel J, et al. The natural history of incidental meningiomas. Neurosurgery. 2003;53:62-70. Resumo

59. Islim AI, Millward CP, Piper RJ, et al. External validation and recalibration of an incidental meningioma prognostic model - IMPACT: protocol for an international multicentre retrospective cohort study. BMJ Open. 2022 Jan 18;12(1):e052705.Texto completo  Resumo

60. Sughrue ME, Rutkowski MJ, Aranda D, et al. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113:1036-42. Resumo

61. Firsching RP, Fischer A, Peters R, et al. Growth rate of incidental meningiomas. J Neurosurg. 1990;73:545-547. Resumo

62. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology. 1998;51:1718-1720. Resumo

63. Herscovici Z, Rappaport Z, Sulkes J, et al. Natural history of conservatively treated meningiomas. Neurology. 2004;63:1133-1134. Resumo

64. Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg. 1995;83:222-224. Resumo

65. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006;105:538-543. Resumo

66. Yoneoka Y, Fujii Y, Tanaka R. Growth of incidental meningiomas. Acta Neurochir (Wien). 2000;142:507-511. Resumo

67. Islim AI, Kolamunnage-Dona R, Mohan M, et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro Oncol. 2020 Feb 20;22(2):278-89.Texto completo  Resumo

68. Marcus HJ, Price SJ, Wilby M, et al. Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg. 2008;22:520-528. Resumo

69. Clark AJ, Jahangiri A, Garcia RM, et al. Endoscopic surgery for tuberculum sellae meningiomas: a systematic review and meta-analysis. Neurosurg Rev. 2013;36:349-359. Resumo

70. Marchetti M, Sahgal A, De Salles AAF, et al. Stereotactic radiosurgery for intracranial noncavernous sinus benign meningioma: International Stereotactic Radiosurgery Society systematic review, meta-analysis and practice guideline. Neurosurgery. 2020 Oct 15;87(5):879-90.Texto completo  Resumo

71. Sughrue ME, Rutkowski MJ, Aranda D, et al. Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. J Neurosurg. 2010;113:1087-1092. Resumo

72. Lee CC, Trifiletti DM, Sahgal A, et al. Stereotactic radiosurgery for benign (World Health Organization Grade I) cavernous sinus meningiomas-International Stereotactic Radiosurgery Society (ISRS) practice guideline: a systematic review. Neurosurgery. 2018 Dec 1;83(6):1128-42. Resumo

73. Palmisciano P, Haider AS, Balasubramanian K, et al. The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials. J Neurooncol. 2022 Aug;159(1):117-33. Resumo

74. Mair MJ, Berghoff AS, Brastianos PK, et al. Emerging systemic treatment options in meningioma. J Neurooncol. 2023 Jan;161(2):245-58.Texto completo  Resumo

75. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986;25:233-242. Resumo

76. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9:156-158. Resumo

77. Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80:313-332. Resumo

78. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86:845-852. Resumo

79. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840-844. Resumo

80. Kondziolka D, Levy EI, Niranjan A, et al. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg. 1999;91:44-50. Resumo

81. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000;50:109-120. Resumo

82. Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012;31:352-360. Resumo

83. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109:187-193. Resumo

84. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63-70.Texto completo  Resumo

85. Andrae N, Kirches E, Hartig R, et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer. 2012;48:1831-41.Texto completo  Resumo

86. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan;17(1):116-21. Resumo

87. Raheja A, Colman H, Palmer CA, et al. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report. J Neurosurg. 2017 Nov;127(5):965-70. Resumo

88. Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014 Mar;117(1):93-101. Resumo

89. Sherman WJ, Raizer JJ. Chemotherapy: What is its role in meningioma? Expert Rev Neurother. 2012 Oct;12(10):1189-95; quiz 1196.Texto completo  Resumo

90. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996 May;84(5):733-6. Resumo

91. Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33:4093-4098. Resumo

92. Goodwin JW, Crowley J, Eyre HJ, et al. A Phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15:75-77. Resumo

93. Schulz S, Pauli SU, Handel M, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6:1865-1874.Texto completo  Resumo

94. Schulz C, Mathieu R, Kunz U, et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011;30:E11. Resumo

95. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69:969-973. Resumo

96. Arena S, Barbieri F, Thellung S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004;66:155-166. Resumo

97. Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014;73:919-923. Resumo

98. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40:271-275. Resumo

99. Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer. 1991;27:416-419. Resumo

100. Wober-Bingol C, Wober C, Marosi C, et al. Interferon-alfa-2b for meningioma. Lancet. 1995;345:331. Resumo

101. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113:2146-2151.Texto completo  Resumo

102. Chamberlain MC. IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol. 2013 May;2(3):227-35.Texto completo  Resumo

103. Ragel BT, Couldwell WT, Wurster RD, et al. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus. 2007;23:E10.Texto completo  Resumo

104. Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97:341-6. Resumo

105. Karsy M, Hoang N, Barth T, et al. Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: human and orthotopic xenograft studies. World Neurosurg. 2016 Feb;86:210-9. Resumo

106. Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18-24. Resumo

107. Milker-Zabel S, Zabel A, Schulz-Ertner D, et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005;61:809-816. Resumo

108. Pettersson-Segerlind J, Orrego A, Lönn S, et al. Long-term 25-year follow-up of surgically treated parasagittal meningiomas. World Neurosurg. 2011 Dec;76(6):564-71. Resumo

109. Sanai N, Sughrue ME, Shangari G, et al. Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg. 2010;112:913-919. Resumo

110. Diluna ML, Bulsara KR. Surgery for petroclival meningiomas: a comprehensive review of outcomes in the skull base surgery era. Skull Base. 2010;20:337-342. Resumo

111. Roth P, Pace A, Le Rhun E, et al. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol. 2021 Feb;32(2):171-82.Texto completo  Resumo

112. Greenhalgh J, Weston J, Dundar Y, et al. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev. 2020 Apr 28;4(4):CD007286.Texto completo  Resumo

113. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;(2):CD004424. Resumo

114. Fluss R, Kobets AJ, Inocencio JF, et al. The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. Clin Neurol Neurosurg. 2021 Feb;201:106460. Resumo

115. Sanford NN, Yeap BY, Larvie M, et al. Prospective, randomized study of radiation dose escalation with combined proton-photon therapy for benign meningiomas. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):787-96.Texto completo  Resumo

116. McClelland S 3rd, Ciporen JN, Mitin T, et al. Long-term stroke risk of single-fraction photon-based stereotactic radiosurgery for meningioma. Clin Neurol Neurosurg. 2018 Oct;173:169-72. Resumo

117. Couldwell WT. Asymptomatic meningiomas. J Neurosurg. 2006;105:536-537. Resumo

118. Nguyen MP, Morshed RA, Dalle Ore CL, et al. Supervised machine learning algorithms demonstrate proliferation index correlates with long-term recurrence after complete resection of WHO grade I meningioma. J Neurosurg. 2023 Jan 1;138(1):86-94. Resumo

119. Claus EB, Black PM, Bondy ML, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer. 2007;110:471-476.Texto completo  Resumo

120. Lall RR, Lall RR, Smith TR, et al. Delayed malignant transformation of petroclival meningioma to chondrosarcoma after stereotactic radiosurgery. J Clin Neurosci. 2014;21:1225-1228. Resumo

121. Osipov V, Ho KC, Krouwer HG, et al. Post-radiation dedifferentiation of meningioma into osteosarcoma. BMC Cancer. 2002;2:34.Texto completo  Resumo

122. Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan;122(1):4-23. Resumo